1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development and benchmarking of the open force field initiative self-consistent force field for proteins and small molecules
    Meeting Abstract

    Cavender, C. E.; Behara, P. K.; Friedman, A. J.; Horton, J. T.; McIsaac, A. R.; Smith, L. G.; Thompson, M. W.; Wagner, J.; Wang, L.; Westbrook, B. R.; more...
    Biophysical Journal (2025)

    Fulltext@MSK | Save
  • Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC) in the monarchE trial
    Meeting Abstract

    Rubenstein, C. S.; Turner, N.; Reis, J. S.; Goetz, M. P.; Desmedt, C.; Chandarlapaty, S.; Sasano, H.; Arteaga, C. L.; Loi, S.; Graff, S. L.; more...
    Breast (2025)

    Fulltext@MSK | Save
  • Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)
    Meeting Abstract

    Loi, S.; Johnston, S.; Arteaga, C.; Graff, S.; Chandarlapaty, S.; Goetz, M.; Desmedt, C.; Sasano, H.; Liu, D.; Rodrik-Outmezguine, V.; more...
    Breast (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    Chen, Y. W.; Liu, L.; Cheng, Y.; Araneta, A.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Runcie, K.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma
    Meeting Abstract

    Khandwala, Y.; Ruthen, N.; Kotecha, R. R.; Russo, P.; Coleman, J.; Reznik, E.; Hakimi, A. A.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Integrin-linked kinase drives drug-tolerant persister cell survival and EMT in response to EGFR inhibition in lung adenocarcinoma
    Meeting Abstract

    Shi, R.; Farnsworth, D. A.; Febres-Aldana, C. A.; Chow, J. L. M.; Sheena, R.; Atwal, T.; Marti, J. L. G.; Thomas, K. N.; Lee, C. M.; Awrey, S. J.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • RRAS and RRAS2 hotspot mutations as novel actionable oncogenic drivers in lung adenocarcinoma
    Meeting Abstract

    Ladanyi, M.; Yang, S. R.; Zhang, T.; de Stanchina, E.; Somwar, R.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save